ScreenerHero

ARDX Ardelyx, Inc.

NAS · US · Healthcare · Biotechnology · ardelyx.com
3.260USD-1.51%Mkt Cap: 841.69M $P/E: —

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap841.69M USD
Enterprise Value825.49M USD
Revenue (TTM)450.89M USD
Gross Profit367.78M USD
Net Income (TTM)-61.60M USD
Revenue/Share1.84 USD
Last Price3.260 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees489
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)11.39
PEG—
EV/EBITDA-25.71
EV/Revenue1.83
P/S1.90
P/B5.54
EPS (TTM)-0.22
EPS (Forward)0.29
52W Range
3.2201% of range8.400
52W High8.400 USD
52W Low3.220 USD
Profitability
Gross Margin90.29%
Oper. Margin-10.28%
EBITDA Margin-7.12%
Profit Margin-15.12%
ROE-36.90%
ROA-12.28%
Growth
Revenue Growth23.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-42.48M USD
CapEx (TTM)1.49M USD
FCF Margin4.54%
FCF Yield2.43%
Net Debt676.99K USD
Net Debt/EBITDA-0.02
Balance Sheet
Debt/Equity1.25
Current Ratio3.34
Quick Ratio2.89
Book Value/Sh0.60 USD
Cash/Share1.13 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.90 USD
Upside (mean)+295.7%
Target Range8.000 USD – 18.00 USD
8.000+295.7% to mean18.00
# Analysts10
Ownership
Shares Out.258.19M
Float210.66M
Insiders3.04%
Institutions73.23%
Short Interest
Short Ratio6.6d
Short % Float10.13%
Short % Out.9.92%
Shares Short25.60M
Short (prev mo.)22.43M
Technical
SMA 503.921 (-16.9%)
SMA 2005.623 (-42.0%)
Beta0.68
S&P 52W Chg16.45%
Avg Vol (30d)4.14M
Avg Vol (10d)4.02M
Technical Indicators
RSI (14)28.2
MACD-0.1996
MACD Signal-0.2235
MACD Hist.+0.0239
BB Upper3.758 USD
BB Middle3.474 USD
BB Lower3.190 USD
BB Width16.35%
ATR (14)0.1390 USD
Vol Ratio (20d)1.27x